Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin add-on therapy to standard of care in hospitalised adult patients with COVID-19 or community-acquired pneumonia
2021-006951-32Phase 3Completed
- Sponsor
- Dompé
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19), community-acquired pneumonia (CAP) and pneumonia comparing Reparixin + standard of care with Standard of care alone (2 arms). Started Jan 2022; status: completed.
02
Drugs
reparixin
03
Conditions
coronavirus disease 2019 (COVID-19)community-acquired pneumonia (CAP)pneumonia
Beyond the preview
Go deeper on 2021-006951-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006951-32.